The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial
Open accessAbstract
BACKGROUND: Despite the heightened risk of serious influenza during infancy, vaccination is not recommended in infants younger than 6 months. We aimed to assess the safety, immunogenicity, and efficacy of maternal immunisation with trivalent inactivated influenza vaccine for protection of infants against a first episode of laboratory-confirmed influenza. METHODS: We did this prospective, active-controlled, observer-blind, randomised phase 4 trial at six referral centres and community health centres in Bamako, Mali. Third-trimester pregnant women (≥28 weeks' gestation) were randomly assigned (1:1), via a computer-generated, centre-specific list with alternate block sizes of six or 12, to receive either trivalent inactivated influenza vaccine or quadrivalent meningococcal vaccine. Study personnel administering vaccines were not masked to treatment allocation, but allocation was concealed from clinicians, laboratory personnel, and participants. Infants were visited weekly until age 6 months to detect influenza-like illness; laboratory-confirmed influenza diagnosed with RT-PCR. We assessed two coprimary objectives: vaccine efficacy against laboratory-confirmed influenza in infants born to women immunised any time prepartum (intention-to-treat population), and vaccine efficacy in infants born to women immunised at least 14 days prepartum (per-protocol population). The primary outcome was the occurrence of a first case of laboratory-confirmed influenza by age 6 months. This trial is registered with ClinicalTrials.gov, number NCT01430689. FINDINGS: We did this trial from Sept 12, 2011, to Jan 28, 2014. Between Sept 12, 2011, and April 18, 2013, we randomly assigned 4193 women to receive trivalent inactivated influenza vaccine (n=2108) or quadrivalent meningococcal vaccine (n=2085). There were 4105 livebirths; 1797 (87%) of 2064 infants in the trivalent inactivated influenza vaccine group and 1793 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6 months. We recorded 5279 influenza-like illness episodes in 2789 (68%) infants, of which 131 (2%) episodes were laboratory-confirmed influenza. 129 (98%) cases of laboratory-confirmed influenza were first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent inactivated influenza vaccine group). In the intention-to-treat population, overall infant vaccine efficacy was 33·1% (95% CI 3·7-53·9); in the per-protocol population, vaccine efficacy was 37·3% (7·6-57·8). Vaccine efficacy remained robust during the first 4 months of follow-up (67·9% [95% CI 35·1-85·3] by intention to treat and 70·2% [35·7-87·6] by per protocol), before diminishing during the fifth month (57·3% [30·6-74·4] and 60·7 [33·8-77·5], respectively). Adverse event rates in women and infants were similar among groups. Pain at the injection site was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inactivated influenza vaccine (n=253 vs n=132; p<0·0001), although 354 [92%] reactions were mild. Obstetrical and non-obstetrical serious adverse events were reported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the trivalent inactivated influenza vaccine group. Presumed neonatal infection was more common in infants in the trivalent inactivated influenza vaccine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0·02). No serious adverse events were related to vaccination. INTERPRETATION: Vaccination of pregnant women with trivalent inactivated influenza vaccine in Mali-a poorly resourced country with high infant mortality-was technically and logistically feasible and protected infants from laboratory-confirmed influenza for 4 months. With adequate financing to procure the vaccine, implementation will parallel the access to antenatal care and immunisation coverage of pregnant women with tetanus toxoid. FUNDING: Bill & Melinda Gates Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Maternal vaccination is a highly effective approach to protect infants from infection.”
From Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy (2017) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“infants of influenza vaccinated mothers were 45–63% less likely to have episodes of proven influenza illness in early infancy (4–6 months of age).”
From Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy (2017) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
New Ballard Score, expanded to include extremely premature infants
Ballard, J. L., Khoury, J. C., Wedig, K., Wang, L., Eilers-Walsman, B. L., & Lipp, R. (1991) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)82056-6 · Cited by 1,961
Effectiveness of maternal influenza immunization in mothers and infants
Zaman, K., Roy, E., Arifeen, S. E., Rahman, M., Raqib, R., Wilson, E., Omer, S. B., Shahid, N. S., Breiman, R. F., & Steinhoff, M. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708630 · Cited by 1,227
Vaccines against influenza WHO position paper – November 2012.
(2012) · PubMed · Cited by 1,122
Nair, H., Brooks, W. A., Katz, M., Roca, A., Berkley, J. A., Madhi, S. A., Simmerman, J. M., Gordon, A., Sato, M., Howie, S., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61051-9 · Cited by 1,006
Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California
Louie, J. K., Acosta, M., Jamieson, D. J., & Honein, M. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910444 · Cited by 647
Influenza vaccination of pregnant women and protection of their infants
Madhi, S. A., Cutland, C. L., Kuwanda, L., Weinberg, A., Hugo, A., Jones, S., Adrian, P. V., van Niekerk, N., Treurnicht, F., Ortiz, J. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401480 · Cited by 556
Effects of influenza on pregnant women and infants
Rasmussen, S. A., Jamieson, D. J., & Uyeki, T. M. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.06.068 · Cited by 431
Roper, M. H., Vandelaer, J. H., & Gasse, F. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61261-6 · Cited by 310
Perinatal outcomes after maternal 2009/H1N1 infection: national cohort study
Pierce, M., Kurinczuk, J. J., Spark, P., Brocklehurst, P., Knight, M., & UKOSS, O. B. O. (2011) · BMJ · doi:10.1136/bmj.d3214 · Cited by 280
Cited by
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6703a1 · Cited by 1,632
Wang, X., Li, Y., O'Brien, K. L., Madhi, S. A., Widdowson, M.-A., Byass, P., Omer, S. B., Abbas, Q., Ali, A., Amu, A., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30545-5 · Cited by 492
Grohskopf, L. A., Alyanak, E., Ferdinands, J. M., Broder, K. R., Blanton, L. H., Talbot, H. K., & Fry, A. M. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7005a1 · Cited by 360
The disease burden of influenza beyond respiratory illness
Macias, A. E., McElhaney, J. E., Chaves, S. S., Nealon, J., Nunes, M. C., Samson, S. I., Seet, B. T., Weinke, T., & Yu, H. (2021) · Vaccine · doi:10.1016/j.vaccine.2020.09.048 · Cited by 371
Mbaeyi, S. A., Bozio, C. H., Duffy, J., Rubin, L. G., Hariri, S., Stephens, D. S., & MacNeil, J. R. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6909a1 · Cited by 321
Metadata
- Authors
- Tapia, M. D., Sow, S. O., Tamboura, B., Tégueté, I., Pasetti, M. F., Kodio, M., Onwuchekwa, U., Tennant, S. M., Blackwelder, W. C., Coulibaly, F., Traoré, A., Keita, A. M., Haidara, F. C., Diallo, F., Doumbia, M., Sanogo, D., DeMatt, E., Schluterman, N. H., Buchwald, A., Kotloff, K. L., Chen, W. H., Orenstein, E. W., Orenstein, L. A. V., Villanueva, J., Bresee, J., Treanor, J., & Levine, M. M.
- Affiliations
- University of Maryland, Baltimore (US)
- Centre Pour le Développement des Vaccins-Mali (ML)
- United States Department of Veterans Affairs (US)
- Children's Hospital of Philadelphia (US)
- Emory University (US)
- Centers for Disease Control and Prevention (US)
- University of Rochester Medicine (US)
- Corresponding author
- Levine, Myron M
- ORCID
- Tapia, Milagritos D
- Sow, Samba O
- Tamboura, Boubou
- Pasetti, Marcela F
- Tennant, Sharon M
- Blackwelder, William C
- Traoré, Awa
- Keita, Adama Mamby
- Haidara, Fadima Cheick
- Diallo, Fatoumata
- Doumbia, Moussa
- Buchwald, Andrea
- Kotloff, Karen L
- Chen, Wilbur H
- Orenstein, Evan W
- Orenstein, Lauren A V
- Villanueva, Julie
- Bresee, Joseph
- Levine, Myron M
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 16
- Issue
- 9
- Pages
- 1026-1035
- ISSN
- 1473-3099 (ISSN-L)
- PMC
- PMC4985566
- OpenAlex
- W2414404462
- Cited by
- 245
- References
- 29
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 15 · 2023: 13 · 2022: 13 · 2021: 27 · 2020: 31 · 2019: 56 · 2018: 30 · 2017: 34 · 2016: 5
- FWCI
- 39.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Infectious Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Bill & Melinda Gates Foundation (OPP1002744)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- maternal immunization, trivalent inactivated influenza vaccine, quadrivalent meningococcal vaccine, vaccine efficacy, vaccine safety, immunogenicity, influenza-like illness, infants under 6 months, Mali, pregnant women, cross-protective immunity, seroconversion, seroconversion rate
- MeSH terms
- Adjuvants, Immunologic, Adult, Female, Humans, Immunization, Immunization Schedule, Infant, Infant, Newborn, Influenza, Human, Influenza Vaccines, Mali, Prospective Studies, Vaccination, Meningococcal Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. https://app.cochat.ai/papers/10.1016/s1473-3099(16)30054-8
- The paper
- Tapia, M. D., Sow, S. O., Tamboura, B., Tégueté, I., Pasetti, M. F., Kodio, M., Onwuchekwa, U., Tennant, S. M., Blackwelder, W. C., Coulibaly, F., Traoré, A., Keita, A. M., Haidara, F. C., Diallo, F., Doumbia, M., Sanogo, D., DeMatt, E., Schluterman, N. H., Buchwald, A., . . . Levine, M. M. (2016). Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(16)30054-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.